• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis.《日本经动脉化疗栓塞术联合索拉非尼治疗中晚期肝细胞癌的疗效：一项回顾性分析》勘误
Clin Drug Investig. 2016 Jan;36(1):93-6. doi: 10.1007/s40261-015-0363-x.
2
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.索拉非尼联合经导管动脉化疗栓塞治疗晚期肝细胞癌的疗效增强。
Jpn J Clin Oncol. 2014 Aug;44(8):711-7. doi: 10.1093/jjco/hyu068. Epub 2014 May 22.
3
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.验证 LCSGJ 提出的晚期肝细胞癌患者经导管动脉化疗栓塞失败或耐药的标准。
Oncology. 2014;87 Suppl 1:32-6. doi: 10.1159/000368143. Epub 2014 Nov 22.
4
Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.经导管动脉化疗栓塞术联合经皮乙醇注射治疗不可切除的大肝细胞癌：局部治疗效果和生存率评估
Hepatogastroenterology. 2001 Sep-Oct;48(41):1409-15.
5
Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.经导管动脉化疗栓塞治疗不可切除肝细胞癌的前瞻性研究：日本和韩国亚洲合作研究。
J Vasc Interv Radiol. 2013 Apr;24(4):490-500. doi: 10.1016/j.jvir.2013.01.003. Epub 2013 Mar 7.
6
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.分子靶向药物索拉非尼在肝细胞癌治疗算法中的定位及日本许多完全缓解病例的意义。
Oncology. 2010 Jul;78 Suppl 1:154-66. doi: 10.1159/000315245. Epub 2010 Jul 8.
7
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌患者的比较。
J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.
8
Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.经导管动脉化疗栓塞术使用米立膦酸-碘油混悬剂治疗不可切除的肝细胞癌。
Jpn J Clin Oncol. 2012 Mar;42(3):175-82. doi: 10.1093/jjco/hyr189. Epub 2011 Dec 30.
9
Hepatectomy with chemoembolization for treatment of hepatocellular carcinoma.肝切除术联合化疗栓塞治疗肝细胞癌。
Hepatogastroenterology. 2003 May-Jun;50(51):750-5.
10
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.索拉非尼联合化疗栓塞和射频消融治疗大的不可切除肝细胞癌的疗效。
Chin Med J (Engl). 2013 Nov;126(22):4270-6.

引用本文的文献

1
Clinical outcomes of hepatocellular carcinoma patients after hepatectomy treated with TACE in combination with sorafenib: a propensity score matched analysis.经肝动脉化疗栓塞术（TACE）联合索拉非尼治疗的肝细胞癌患者肝切除术后的临床结局：一项倾向评分匹配分析
Transl Cancer Res. 2023 May 31;12(5):1088-1099. doi: 10.21037/tcr-22-2784. Epub 2023 May 8.
2
Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival.印度西北部的肝细胞癌：一项聚焦于流行病学、危险因素和生存情况的回顾性研究
J Gastrointest Cancer. 2022 Dec;53(4):921-929. doi: 10.1007/s12029-021-00712-z. Epub 2021 Sep 22.
3
High cholinesterase predicts tolerance to sorafenib treatment and improved prognosis in patients with transarterial chemoembolization refractory intermediate stage hepatocellular carcinoma.高胆碱酯酶预示着经动脉化疗栓塞难治性中期肝细胞癌患者对索拉非尼治疗的耐受性及预后改善。
Mol Clin Oncol. 2020 Jan;12(1):60-68. doi: 10.3892/mco.2019.1949. Epub 2019 Nov 18.
4
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.经动脉化疗栓塞联合索拉非尼与索拉非尼单药治疗巴塞罗那临床肝癌分期 B/C 期患者的安全性和有效性。
BMC Cancer. 2017 Sep 12;17(1):645. doi: 10.1186/s12885-017-3545-5.
5
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.使用FT率评估索拉非尼对肝细胞癌患者总生存期的疗效：一种设计的指标。
Adv Ther. 2017 May;34(5):1097-1108. doi: 10.1007/s12325-017-0524-9. Epub 2017 Apr 7.

Erratum to: Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis.

作者信息

Ohki Takamasa, Sato Koki, Yamagami Mari, Ito Daisaku, Yamada Tomoharu, Kawanishi Koki, Kojima Kentaro, Seki Michiharu, Toda Nobuo, Tagawa Kazumi

机构信息

Department of Gastroenterology, Mitsui Memorial Hospital, Kanda-Izumi-cho 1, Chiyoda-ku, Tokyo, 101-8643, Japan.

出版信息

Clin Drug Investig. 2016 Jan;36(1):93-6. doi: 10.1007/s40261-015-0363-x.

DOI:10.1007/s40261-015-0363-x
PMID:26728977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4969905/
Abstract
摘要